NSAV Net Savings Link Inc (PK)

NSAV CANNABIS DIVISION OPENS SHANGHAI FACILITY

CRESCO, PA -- May 15, 2017 -- InvestorsHub NewsWire -- Net Savings Link, Inc. (OTC: NSAV) announced today that the Company’s Medical Cannabis Technology Division has officially opened its location in Shanghai, China. The Company views this as a major opportunity to expand its medical cannabis technology business in the world’s largest city and second largest consumer market, as China is the world’s largest producer of cannabis sativa seeds, accounting for nearly 40% of global production. NSAV will be accompanied in this project by its joint venture partner, AMC Shanghai. AMC is an international health care group, whose Medical Care and Insurance Division already has several projects under development with NSAV. Photos of the Shanghai joint venture facility can be viewed on the NSAV corporate website.

http://netsavlink.com/shanghai-office

Last week NSAV announced that it has signed a definitive agreement to acquire world renowned Chinese medical software company, Shanghai based Vital Strategic Research Institute (VSRI). VSRI is a medical research firm with a long history of expertise in design, clinical trials and global research. VSRI has collaborated with pharmaceutical giants such as Pfizer and Bristol-Myers Squibb. Under NSAV’s guidance, VSRI will conduct extensive clinical research studies into the medical uses and benefits of cannabis and hemp related products. VSRI has websites in both English and Chinese.

http://www.vitalstrategic.com/collaborators.html

http://www.vitalstrategic.com.cn/Home/cooperatingagency

NSAV would also like to remind its shareholders of the June 1, 2017 record date for the Company’s 10% dividend.

James Tilton, president of NSAV stated, “I am extremely pleased that our medical cannabis technology business now has a presence in China. Besides accounting for nearly 40% of the global production of cannabis sativa seeds, Chinese companies have 309 out of the 606 patents filed around the world that relate to cannabis. As one who has lived and worked in Shanghai, I can personally appreciate what an amazing city it is.”

NSAV's vision is the establishment of a fully integrated technology company that provides turnkey technological solutions to the medical cannabis industry, as well as other areas of the medical industry. Over time, the Company plans to provide a wide range of services such as software solutions, e-commerce, advisory services, financial services, patents and trademarks and information technology.

For further information please contact NSAV at 1 (570-595-2432) or jamestilton@netsavingslinkinc.com.

The NSAV corporate website can be accessed at  http://netsavlink.com

The NSAV Twitter account can be accessed at  https://twitter.com/NSAV_MJTechCo

The NSAV Facebook account can be accessed at  https://www.facebook.com/Net-Savings-Link-Inc-768628693317257/

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that, all forward-looking statements involve risks and uncertainties, including without limitation, the ability of Net Savings Link, Inc. to accomplish its stated plan of business. Net Savings Link, Inc. believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward- looking statements included herein, the inclusion of such information should not be regarded as a representation by Net Savings Link, Inc. or any other person.

Net Savings Link (PK) (USOTC:NSAV)
Historical Stock Chart
From Mar 2024 to Apr 2024

Net Savings Link (PK) (USOTC:NSAV)
Historical Stock Chart
From Apr 2023 to Apr 2024